PL3980031T3 - Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe - Google Patents

Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe

Info

Publication number
PL3980031T3
PL3980031T3 PL20809730.3T PL20809730T PL3980031T3 PL 3980031 T3 PL3980031 T3 PL 3980031T3 PL 20809730 T PL20809730 T PL 20809730T PL 3980031 T3 PL3980031 T3 PL 3980031T3
Authority
PL
Poland
Prior art keywords
povidone
iodine
infection
prevention
topical application
Prior art date
Application number
PL20809730.3T
Other languages
English (en)
Inventor
Peter Molloy
Stephen Goodall
Original Assignee
Firebrick Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902006A external-priority patent/AU2019902006A0/en
Application filed by Firebrick Pharma Limited filed Critical Firebrick Pharma Limited
Publication of PL3980031T3 publication Critical patent/PL3980031T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20809730.3T 2019-06-10 2020-06-10 Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe PL3980031T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902006A AU2019902006A0 (en) 2019-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2020900489A AU2020900489A0 (en) 2020-02-20 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
PCT/AU2020/050586 WO2020232515A1 (en) 2019-06-10 2020-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Publications (1)

Publication Number Publication Date
PL3980031T3 true PL3980031T3 (pl) 2026-04-20

Family

ID=73459166

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20809730.3T PL3980031T3 (pl) 2019-06-10 2020-06-10 Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe

Country Status (18)

Country Link
US (3) US11246887B2 (pl)
EP (1) EP3980031B1 (pl)
JP (1) JP2022538711A (pl)
KR (1) KR20220018570A (pl)
CN (1) CN114258303A (pl)
AU (1) AU2020280226B2 (pl)
BR (1) BR112021024916A2 (pl)
CA (1) CA3141483A1 (pl)
CL (1) CL2021003208A1 (pl)
ES (1) ES3058227T3 (pl)
IL (1) IL288742A (pl)
MX (1) MX2021015110A (pl)
MY (1) MY207382A (pl)
PH (1) PH12021553050A1 (pl)
PL (1) PL3980031T3 (pl)
SG (1) SG11202112735QA (pl)
WO (1) WO2020232515A1 (pl)
ZA (1) ZA202109360B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3980031T3 (pl) 2019-06-10 2026-04-20 Firebrick Pharma Limited Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe
US11179575B2 (en) 2019-10-15 2021-11-23 Cedars-Sinai Medical Center Internal ultraviolet therapy
NL2025641B1 (en) * 2020-04-17 2023-06-22 Veloce Biopharma Llc Methods and compositions for improved treatment of sinus disease
CA3180198A1 (en) * 2020-06-10 2021-12-16 Peter Molloy Improved virucidal formulations
MX2023007926A (es) * 2020-12-31 2023-10-12 Ntby Moss Llc Formulaciones de un espray nasal profiláctico y metodos de uso y fabricación del mismo. .
EP4285920A4 (en) 2021-02-01 2024-10-23 Dermopartners, S.L. COMPOSITION INTENDED FOR USE IN THE FORM OF NASAL DROPS AND NEBULIZERS WITH ANTIVIRAL ACTION
IL308209A (en) * 2021-05-05 2024-01-01 Cedars Sinai Medical Center Exposure to UVA light increases mitochondrial antiviral protein expression in tracheal cells through cell-to-cell communication and its uses
FR3122572A1 (fr) * 2021-05-07 2022-11-11 Nadine GRISLAIN Composition pharmaceutique bioadhésive comprenant du PVPI
AU2021203846B2 (en) * 2021-06-10 2022-11-24 Firebrick Pharma Limited Virucidal formulations containing povidone-iodine
CO2021016391A1 (es) * 2021-11-30 2023-06-09 Quifarmedical Company S A S Composición farmacéutica líquida antiviral contra sars-cov-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4523589A (en) 1983-06-29 1985-06-18 Krauser Robert S Method and apparatus for treating ailments
JPH04173726A (ja) 1990-11-05 1992-06-22 Nippon Zetotsuku Kk 歯磨剤組成物
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
JPH09151127A (ja) 1995-09-29 1997-06-10 Taisho Pharmaceut Co Ltd 咽頭疾患用組成物
JP2000169378A (ja) 1998-12-10 2000-06-20 Taisho Pharmaceut Co Ltd 咽頭疾患用組成物
US20060122082A1 (en) 2000-02-17 2006-06-08 Leonard Paul Foam/spray producing compositions and dispensing system therefor
US6696041B2 (en) * 2002-03-20 2004-02-24 Richard L. Hansen Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use
EP1556021B1 (en) * 2002-10-24 2007-12-19 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
JP2004352642A (ja) 2003-05-29 2004-12-16 Meiji Seika Kaisha Ltd ウイルス感染症予防剤
CN1203864C (zh) 2003-07-23 2005-06-01 南京大学 聚维酮碘喷雾剂
EP1819229A2 (en) 2004-12-09 2007-08-22 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
US11986491B2 (en) 2011-06-22 2024-05-21 Iview Therapeutics, Inc. Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
CN103751274B (zh) * 2014-02-20 2016-08-17 河北旺达饲料兽药开发有限公司 一种治疗鸭、鹅黄病毒感染的药物组合物及其制备方法
HRP20211810T1 (hr) * 2014-07-23 2022-03-04 Firebrick Pharma Limited Liječenje i prevencija prehlade korištenjem povidon-joda
KR20170033925A (ko) 2015-09-17 2017-03-28 송경진 항바이러스 및 세균용 스프레이 조성물
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
PL3980031T3 (pl) * 2019-06-10 2026-04-20 Firebrick Pharma Limited Zapobieganie zakażeniom wysoce patogennymi wirusami poprzez miejscowe stosowanie jodopowidonu na błony śluzowe

Also Published As

Publication number Publication date
AU2020280226A1 (en) 2022-01-06
WO2020232515A1 (en) 2020-11-26
CN114258303A (zh) 2022-03-29
JP2022538711A (ja) 2022-09-06
BR112021024916A2 (pt) 2022-02-15
EP3980031B1 (en) 2025-12-17
US20220088067A1 (en) 2022-03-24
US11969441B2 (en) 2024-04-30
ZA202109360B (en) 2023-10-25
EP3980031A4 (en) 2022-08-17
MY207382A (en) 2025-02-25
IL288742A (en) 2022-02-01
CA3141483A1 (en) 2020-11-26
ES3058227T3 (en) 2026-03-09
PH12021553050A1 (en) 2023-07-31
US20220168338A1 (en) 2022-06-02
US20200384016A1 (en) 2020-12-10
MX2021015110A (es) 2022-02-22
CL2021003208A1 (es) 2022-09-30
EP3980031A1 (en) 2022-04-13
KR20220018570A (ko) 2022-02-15
US11246887B2 (en) 2022-02-15
SG11202112735QA (en) 2021-12-30
EP3980031C0 (en) 2025-12-17
AU2020280226B2 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
IL288742A (en) A preparation that recognizes povidone-iodine for topical administration through mucosal membranes to prevent viral infections
EP3996716A4 (en) COMPOUNDS FOR TREATMENT OF INFLUENCE VIRUS INFECTION
JOP20180123A1 (ar) مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية
MX2019009443A (es) Metodos para tratar la influenza.
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
WO2016142445A3 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
PH12017500207A1 (en) Indoles for use in influenza virus infection
MY197408A (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
CA3010327A1 (en) Aryl substituted pyrimidines for use in influenza virus infection
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
BR112017011478A2 (pt) composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
WO2018109042A3 (en) Antimicrobial peptides
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
HK1222339A1 (zh) 金属-β-内酰胺酶的抑制剂
HK40067701A (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2019902006A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2018902045A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2018901988A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2017902102A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
EA201791995A1 (ru) Средство для лечения респираторной инфекции
AU2020900489A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2016902095A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
IL288713A (en) Methods for treating viral infections
HK1206594A1 (en) Materials and methods for prevention and treatment of viral infections